Download - PDF

ABSTRACT

Objectives:

Andrographis paniculata has in vitro inhibitory activity against TNF-a, IL-1p and NF-KB. A pilot study of A. paniculata extract (HMPL-004) suggested similar ef.cacy to mesalamine for ulcerative colitis.

Methodes:

A randomized, double-blind, placebo-controlled trial evaluated the ef.cacy of A. paniculata extract (HMPL-004) in 224 adults with mild-to-moderate ulcerative colitis. Patients were randomized to A. paniculata extract (HMPL-004) 1,200 mg or 1,800 mg daily or placebo for 8 weeks.

Results:

In total, 45 and 60 % of patients receiving A. paniculata 1,200 mg and 1,800 mg daily, respectively, were in clinical response at week 8, compared with 40 % of those who received placebo (P=0.5924 for 1,200 mg vs. placebo and P=0.0183 for 1,800 mg vs. placebo). In all, 34 and 38 % of patients receiving A. paniculata 1,200 mg and 1,800 mg daily, respectively, were in clinical remission at week 8, compared with 25 % of those who received placebo (P=0.2582 for 1,200 mg vs. placebo and P=0.1011 for 1,800 mg vs. placebo). Adverse events developed in 60 and 53 % of patients in the A. paniculata 1,200 mg and 1,800 mg daily groups, respectively, and 60 % in the placebo group.

Results:

Patients with mildly to moderately active ulcerative colitis treated with A. paniculata extract (HMPL-004) at a dose of 1,800 mg daily were more likely to achieve clinical response than those receiving placebo.

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538174/